{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:46:27Z","timestamp":1783637187905,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.drugalcdep.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T22:49:34Z","timestamp":1550184574000},"page":"168-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions"],"prefix":"10.1016","volume":"197","author":[{"given":"Sara","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remar","family":"Mangaoil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Cleverley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-1854","authenticated-orcid":false,"given":"Martine","family":"Puts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0005","series-title":"The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","author":"American Society of Addiction Medicine","year":"2015"},{"issue":"5","key":"10.1016\/j.drugalcdep.2019.02.007_bib0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/00952990.2011.596982","article-title":"Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial","volume":"37","author":"Back","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0015","doi-asserted-by":"crossref","first-page":"E344","DOI":"10.9778\/cmajo.20140089","article-title":"Sex differences in outcomes of methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis","volume":"3","author":"Bawor","year":"2015","journal-title":"CMAJ Open"},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2019.02.007_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jnr.23963","article-title":"Sex differences, gender and addiction","volume":"95","author":"Becker","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J. Med. Libr. Assoc."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsat.2017.01.019","article-title":"Quality of life as an outcome of opioid use disorder treatment: a systematic review","volume":"76","author":"Bray","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0035","series-title":"A Guideline for the Clinical Management of Opioid Use Disorder","author":"British Columbia Centre on Substance Use","year":"2017"},{"issue":"9","key":"10.1016\/j.drugalcdep.2019.02.007_bib0040","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0045","series-title":"Joint Statment of Action to Address the Opioid Crisis: A Collective Response","author":"Canadian Centre on Substance Use and Addiction","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0050","series-title":"Prescription Opioids","author":"Canadian Centre on Substance Use and Addiction","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0055","series-title":"What Is Gender? What Is Sex?","author":"Canadian Institutes of Health Research","year":"2014"},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/1552-6909.12306","article-title":"Experiences of mothers of infants with neonatal abstinence syndrome in the neonatal intensive care unit","volume":"43","author":"Cleveland","year":"2014","journal-title":"J. Obstet. Gynecol. Neonatal Nurs."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0065","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. n.d. Available at www.covidence.org."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0070","series-title":"C larivate Analytics, Philadelphia, USA","author":"EndNote reference management software","year":"2019"},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/03630242.2016.1160967","article-title":"Gender differences in treatment progress of drug-addicted patients","volume":"57","author":"Fernandez-Montalvo","year":"2017","journal-title":"Women Health"},{"issue":"12","key":"10.1016\/j.drugalcdep.2019.02.007_bib0080","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"5","key":"10.1016\/j.drugalcdep.2019.02.007_bib0085","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpain.2004.01.007","article-title":"Sex differences in opioid analgesia: clinical and experimental findings","volume":"8","author":"Fillingim","year":"2004","journal-title":"Eur. J. Pain"},{"issue":"9","key":"10.1016\/j.drugalcdep.2019.02.007_bib0090","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","article-title":"Buprenorphine versus methadone maintenance for the treatment of opioid dependence","volume":"94","author":"Fischer","year":"1999","journal-title":"Addiction"},{"issue":"10","key":"10.1016\/j.drugalcdep.2019.02.007_bib0095","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0100","series-title":"National Report: Apparent Opioid-related Deaths in Canada (released June 2018)","author":"Government of Canada","year":"2018"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.05.012","article-title":"Substance abuse treatment entry, retention, and outcome in women: a review of the literature","volume":"86","author":"Greenfield","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0110","series-title":"Opioid Use Disorder: Care for People 16 Years of Age and Older","author":"Health Quality Ontario","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0115","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0","author":"Higgins","year":"2011"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"20","key":"10.1016\/j.drugalcdep.2019.02.007_bib0125","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.drugalcdep.2019.02.007_bib0130","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/10550490590949569","article-title":"Males and females differ in response to opioid agonist medications","volume":"14","author":"Jones","year":"2005","journal-title":"Am. J. Addict."},{"issue":"9358","key":"10.1016\/j.drugalcdep.2019.02.007_bib0140","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.drugalcdep.2019.02.007_bib0145","first-page":"5","article-title":"Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients","volume":"10","author":"Kamien","year":"2008","journal-title":"Heroin Addict. Relat. Clin. Probl."},{"issue":"6","key":"10.1016\/j.drugalcdep.2019.02.007_bib0150","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00005053-199306000-00004","article-title":"Buprenorphine versus methadone maintenance for opioid dependence","volume":"181","author":"Kosten","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"issue":"5","key":"10.1016\/j.drugalcdep.2019.02.007_bib0155","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1360-0443.2002.00090.x","article-title":"A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway","volume":"97","author":"Krook","year":"2002","journal-title":"Addiction"},{"issue":"10118","key":"10.1016\/j.drugalcdep.2019.02.007_bib0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.drugalcdep.2019.02.007_bib0165","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"issue":"14","key":"10.1016\/j.drugalcdep.2019.02.007_bib0170","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.drugalcdep.2019.02.007_bib0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jsat.2006.04.005","article-title":"HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone","volume":"31","author":"Lott","year":"2006","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jclinepi.2018.01.009","article-title":"Non-corresponding authors in the era of meta-analyses","volume":"98","author":"Manca","year":"2018","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2019.02.007_bib0185","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"issue":"10141","key":"10.1016\/j.drugalcdep.2019.02.007_bib0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(18)31203-0","article-title":"Women and opioids: something different is happening here","volume":"392","author":"Mazure","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2012.12.007","article-title":"Gender differences in a clinical trial for prescription opioid dependence","volume":"45","author":"McHugh","year":"2013","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0200","article-title":"Sex and gender differences in substance use disorders","author":"McHugh","year":"2017","journal-title":"Clin. Psychol. Rev."},{"issue":"5","key":"10.1016\/j.drugalcdep.2019.02.007_bib0205","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0000000000000510","article-title":"Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058","volume":"68","author":"Metzger","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"9","key":"10.1016\/j.drugalcdep.2019.02.007_bib0210","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.drugalcdep.2019.02.007_bib0215","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/heapol\/czw037","article-title":"How to do (or not to do)\u2026 gender analysis in health systems research","volume":"31","author":"Morgan","year":"2016","journal-title":"Health Policy Plan."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0220","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0225","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00213-005-2239-x","article-title":"Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers","volume":"179","author":"Neri","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0230","first-page":"43","article-title":"Cocaine use in buprenorphine-maintained vs. methadone-maintained patients","volume":"3","author":"Oliveto","year":"1994","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0235","series-title":"Expecting Better: Improving Health and Rights for Pregnant Women Who Use Drugs","author":"Open Society Foundations","year":"2018"},{"issue":"2","key":"10.1016\/j.drugalcdep.2019.02.007_bib0240","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.drugalcdep.2013.06.024","article-title":"Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial","volume":"133","author":"Otiashvili","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","article-title":"Buprenorphine: a controlled clinical trial in the treatment of opioid dependence","volume":"60","author":"Pani","year":"2000","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2014.10.003","article-title":"Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia","volume":"50","author":"Piralishvili","year":"2015","journal-title":"J. Subst. Abuse Treat."},{"issue":"12","key":"10.1016\/j.drugalcdep.2019.02.007_bib0260","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2019.02.007_bib0265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.drugalcdep.2019.02.007_bib0270","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpsyc.1997.01830200041006","article-title":"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse","volume":"54","author":"Schottenfeld","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00005053-199801000-00006","article-title":"Prognostic factors in Buprenorphine- versus methadone-maintained patients","volume":"186","author":"Schottenfeld","year":"1998","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0280","article-title":"Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys","author":"Schwienteck","year":"2018","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0285","doi-asserted-by":"crossref","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"5","key":"10.1016\/j.drugalcdep.2019.02.007_bib0290","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study","volume":"11","author":"Soyka","year":"2008","journal-title":"Int. J. Neuropsychopharmcol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0295","doi-asserted-by":"crossref","DOI":"10.1186\/s40352-015-0015-5","article-title":"Pregnant women and substance use: fear, stigma, and barriers to care","volume":"3","author":"Stone","year":"2015","journal-title":"Health Justice"},{"issue":"4","key":"10.1016\/j.drugalcdep.2019.02.007_bib0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02247469","article-title":"Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users","volume":"116","author":"Strain","year":"1994","journal-title":"Psychopharmacology (Berl.)"},{"issue":"7","key":"10.1016\/j.drugalcdep.2019.02.007_bib0305","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.151.7.1025","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence","volume":"151","author":"Strain","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","article-title":"Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index","volume":"16","author":"Strain","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"issue":"145","key":"10.1016\/j.drugalcdep.2019.02.007_bib0315","article-title":"Why sex and gender matter in implementation research","volume":"16","author":"Tannenbaum","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.02.007_bib0320","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.9778\/cmajo.20160051","article-title":"Sex and gender considerations in Canadian clinical practice guidelines: a systematic review","volume":"5","author":"Tannenbaum","year":"2017","journal-title":"CMAJ Open"},{"issue":"12","key":"10.1016\/j.drugalcdep.2019.02.007_bib0325","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.drugalcdep.2019.02.007_bib0330","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.drugalcdep.2019.02.007_bib0335","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1111\/dar.12608","article-title":"Large variation in measures used to assess outcomes of opioid dependence treatment: a systematic review of longitudinal observational studies","volume":"37","author":"Wiessing","year":"2018","journal-title":"Drug Alcohol Rev."},{"issue":"3","key":"10.1016\/j.drugalcdep.2019.02.007_bib0340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","article-title":"HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial","volume":"66","author":"Woody","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618306434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618306434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T10:25:07Z","timestamp":1560507907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618306434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":68,"alternative-id":["S0376871618306434"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.007","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}